UPDATED: McKesson's German unit raided in price collusion probe

McKesson’s big move into international markets hit a snag Thursday when German antitrust regulators raided one of its operations, along with 8 other wholesalers, as part of a probe into whether drug distributors have colluded on prices.  

Germany’s Cartel Office authorities confirmed the raid to Reuters but refused to say what companies had been targeted. In a written statement, German distributor Gehe confirmed to the news service that its offices were searched and that the company was cooperating with antitrust authorities there. A McKesson spokeswoman Monday confirmed the "visit" to FiercePharmaManufacturing  but declined to comment further. According to Germany’s Handelsblatt, 5 companies dominate the €29-billion market.

McKesson picked up Gehe in its 2014, $5.4 billion deal for EU drug wholesaler Celesio. It acquired Celesio, which has operations in about 16 EU countries in its initial step to move into international markets. Since then, San Francisco-based McKesson has added other international operations.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

While never accused of colluding with other players, McKesson ($MCK) has been accused of taking advantage of situations to manipulate prices. Several years ago, it paid more than $355 million to settle state and federal litigation that accused the wholesaler of reporting prices in such a way that allowed for higher wholesale prices. McKesson never acknowledged that it did anything wrong, saying that it settled the cases to avoid the “uncertainty of litigation.”

The raid on McKesson is the second action tied to alleged “anti-competitive” practices in a week. The top court of the European Commission last week upheld €146 million ($164 million) in fines against Denmark’s Lundbeck and 5 drugmakers that participated in pay-for-delay deals some years back. The EU fined Lundbeck and others in 2013 for working out agreements to delay copies of the blockbuster antidepressant Celexa, adding millions of euros to what consumers and governments health programs paid for the drug.

- read the Reuters story

Related Articles:
McKesson buying Celesio for $5.4B as wholesalers seek pricing leverage
Europe's top court upholds pay-for-delay fines against Lundbeck and others
Wholesaler McKesson settles another price-manipulation suit


Suggested Articles

Roche's Perjeta is looking to build its case as an add-on treatment to standard-of-care Herceptin plus chemo in HER2-positive breast cancer patients.

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.